Q2 2026 saw resumed Ximluci shipments, 7% EU market share, and SEK 46.8M revenue. Gross margin was 5% due to one-offs, but cost reductions are expected from mid-2027. U.S. FDA decision for Ximluci is due in October, and new biosimilar programs are advancing.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.